Canaccord's Tim Hoff saw Azure Minerals coming before it happened. He thinks Zambian copper junior Prospect has similar credentials.

Strength in healthcare and financial stocks has kept the ASX on life support, retaining some gains to lift 0.21pc overall.

Guy Le Page looks at Cygnus Metals and its big plans to build out a high-grade copper-gold opportunity through additional discoveries.

A home-grown leader in sleep and neural analysis, Compumedics is tackling the burgeoning US home sleep testing market.

Meteoric Resources has been up to 36.3% higher after releasing a maiden resource estimate for the Bara do Pacu licence at its Caldeira REE project in Brazil.

Neuren Pharmaceuticals and its US partner Acadia have been blitzing it with the Rett syndrome treatment Daybue.

Graphene is gaining serious traction in Europe after major funding, while in Australia, Adisyn is positioning itself as a key ...

ASX nudges up on US tariff hopes, but Bellevue Gold gets hammered after a capital raise, while HUB24 shines with record inflows.

Tony turns his attention to pivotal phase 3 trials and what mix of make or break biotechs you should have in your portfolio.

The US FDA has approved EBR System's leadless pacemaker WISE, the only heart device able to deliver left-ventricle ...

Meteoric (ASX:MEI) has added tonnes to its Brazilian portfolio, making it one of the highest grade ionic clay rare earth deposits globally.

Climbing energy and gold stocks have lifted the ASX in early trading, boosting the bourse 0.3pc in the first hour.